News25/Ratings12
News · 26 weeks55+50%
2025-12-282026-06-21
Mix3290d
- Insider11(34%)
- SEC Filings10(31%)
- Other7(22%)
- Offering2(6%)
- Earnings1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Iwicki Mark T4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Manke Isaac4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Laporte Kathleen4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Tzianabos Arthur4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Grayzel David S.4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Xu Diyong4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Thistle Mary4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERSEC Form 4 filed by Director Lundberg Sven Ante4 - Q32 Bio Inc. (0001661998) (Issuer)
- SECSEC Form 8-K filed by Q32 Bio Inc.8-K - Q32 Bio Inc. (0001661998) (Filer)
- INSIDERNew insider Atlas Venture Opportunity Fund Ill, L.P. claimed ownership of 625,000 shares (SEC Form 3)3 - Q32 Bio Inc. (0001661998) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Q32 Bio Inc.SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)
- SECSEC Form SCHEDULE 13G filed by Q32 Bio Inc.SCHEDULE 13G - Q32 Bio Inc. (0001661998) (Subject)
- INSIDERDirector Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- INSIDERDirector Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)4 - Q32 Bio Inc. (0001661998) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)
- SECQ32 Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Announces $55 Million Private Placement FinancingWALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and pre-funded warrants for an aggregate of approximately $55 million.In this private placement, the Company has agreed to issue and sell to such institutional and accredited investors (i) 6,725,000 shares (the "Shares") of the Company's common stock, $0.0001 par
- ANALYSTCantor Fitzgerald initiated coverage on Q32 BioCantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.SCHEDULE 13G/A - Q32 Bio Inc. (0001661998) (Subject)
- SECSEC Form 10-Q filed by Q32 Bio Inc.10-Q - Q32 Bio Inc. (0001661998) (Filer)
- SECQ32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Q32 Bio Inc. (0001661998) (Filer)
- PRQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 ---- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) ---- Completed $10.5 million registered direct offering (RDO) ---- Cash and cash equivalents of $50.8 million as of March 31, 2026, combined with guaranteed near-term milestone payments from ADX-097 asset sale and proceeds from sales under at-the-market (ATM) program received after the end of the quarter, are expected to provide financial runway into 1H'2028 --WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innov
QTTB FAQ
6 questionsWhere does QTTB stock trade?
Q32 Bio Inc. (QTTB) is listed on NASDAQ.What sector and industry is QTTB in?
Q32 Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Q32 Bio Inc. go public?
Q32 Bio Inc. (QTTB) completed its IPO in 2018.What are analysts saying about QTTB?
Q32 Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-05-18.What companies are similar to QTTB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare QTTB side-by-side with any of them on Quantisnow.How can I track QTTB on Quantisnow?
Quantisnow aggregates Q32 Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QTTB to receive live email and push alerts on every new disclosure.